# DeepKinase

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/deepkinase

- Industry: Biotechnology
- Headquarters: Zhuhai, China
- Website: www.deepkinase.com
- Total disclosed funding: $15M
- Latest round: Series A (Mar 29, 2023)
- Investors on record: 3

## About

Based in Zhuhai, China and founded in 2019, DeepKinase operates as a precision medicine technology that focuses on developing clinical proteomics technologies. The company has set up branch offices in Beijing, Shanghai, Kunshan and Ontario. The founder as well as the CEO of the company, Naizhong Zheng, is also the co-founder of Mega Genomics. The CSO, Shuncheng Li, is a tenured professor in the Department of Biochemistry at the University of Western Ontario. In May 2023, DeepKinase completed a series A+ funding.

The company's main product is its self-developed DeepKinase deep fully phosphorylated kinase proteomic platform, DoTK. The platform consists of three main sample processing technology platforms, a method package and mass spectrometry platform, and a database and bioinformatics AI platform. It also developed DoTD, DoTF, DoTB and other service platforms. DeepKinase has also launched a complete range of universal kits for the enrichment of the phosphorylated tyrosine kinase TyrosineKinase. The products and technologies can be used in tumor detection and drug development areas.

## Funding rounds

- Series A, Mar 29, 2023, $15M — Frees Fund, Lapam Capital, BioTrack Capital

## Investors

- Frees Fund (https://capitalatlas.ai/funds/frees-fund) — Series A
- Lapam Capital (https://capitalatlas.ai/funds/lapam-capital) — Series A
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Series A